Corporate ActionJun 16, 2026, 12:41 PM
Tarsier Pharma to Issue 927K Shares from SAFE Conversions
AI Summary
Tarsier Pharma Ltd. filed an amendment to its F-1 registration statement, detailing recent sales of unregistered securities and indemnification provisions for directors and officers. The company plans to issue 927,449 ordinary shares upon its initial public offering, resulting from the conversion of various SAFEs issued in 2024 and 2025. Additionally, the company granted options for over 2.8 million ordinary shares and issued 8,900 shares from option exercises under its 2018 Incentive Plan. The filing also outlines the company's indemnification and exculpation policies for office holders, in accordance with Israeli law.
Key Highlights
- Tarsier Pharma will issue 927,449 ordinary shares upon IPO from SAFE conversions.
- In 2024, the company issued $2.2 million in SAFEs to accredited investors.
- Of the 2024 SAFEs, $300,000 converted into 100,020 ordinary shares between January and February 2026.
- In 2025, the company issued $2.1 million in SAFEs, including a $100,000 May 2025 SAFE and $2.0 million November/December 2025 SAFEs.
- May 2025 SAFE includes a warrant for 100% of the purchase amount, exercisable for two years post-equity financing.
- November 2025 SAFEs include warrants for 200% of the purchase amount, exercisable for three years post-equity financing.
- Options for 2,865,550 ordinary shares were granted under the 2018 Incentive Plan with a weighted average exercise price of $1.45 per share.
- 8,900 ordinary shares were issued upon exercise of options under the 2018 Incentive Plan.
Price Impact
More from TARX